Trust Company’s Moderna MRNA Stock Holding History

Trust Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4K	Hold	20	–	–	﹤0.01%	573
2026 Q1	$1.02K	Buy	+20	New	+$933	﹤0.01%	572

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Trust Company's MRNA Position: Q2 2026 in Review

Trust Company held its Moderna (MRNA) position steady in Q2 2026 at 20 shares worth $1.4K. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Trust Company first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Trust Company held 20 shares of Moderna worth $1.4K as of Q2 2026.
Trust Company left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #573 holding.
Trust Company first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.